Scientists have developed a promising new blood test that identified early-stage breast cancer with 95% accuracy in an initial study. Even more remarkably, the test may help predict whether cancer will return after treatment — potentially changing how doctors detect and monitor one of the most common cancers affecting women worldwide.
A groundbreaking discovery in cancer research is offering new hope for millions of women.
Researchers from the Weizmann Institute of Science and the Hebrew University of Jerusalem have developed an experimental blood test that can identify molecular signs of breast cancer, even when tumors are still very small.
The findings, published on November 11, 2026, in the prestigious scientific journal Nature, suggest that a simple blood sample could one day help doctors detect breast cancer earlier and identify patients at greater risk of recurrence.
In the study, the technology achieved approximately 95% accuracy in distinguishing women with early-stage breast cancer from healthy women.
But researchers discovered something potentially even more important.
The blood test was also able to identify molecular signals associated with aggressive cancer cells that may contribute to the disease returning after treatment.
This could eventually help doctors make more personalized treatment and monitoring decisions.
However, the technology is still experimental and requires further clinical validation before it can be used routinely.
A Blood Test That Could Detect Breast Cancer Before Symptoms Appear
Breast cancer is among the most frequently diagnosed cancers in women worldwide.
Although treatment has improved considerably, early detection remains one of the most important factors influencing outcomes.
Currently, mammography is a primary screening method used to identify suspicious changes in breast tissue.
However, mammograms are not perfect.
Some tumors can be difficult to detect, particularly in women with dense breast tissue.
Dense breasts contain higher proportions of glandular and connective tissue, which can make abnormalities harder to distinguish on mammographic images.
This is where the new blood test could offer an important advantage.
Instead of relying on images of breast tissue, the technology analyzes molecular changes circulating in the bloodstream.
These changes may reveal the presence of cancer even when a tumor is relatively small.
During the research, scientists successfully identified early-stage breast cancer in women whose tumors measured no more than two centimeters.
The researchers also reported encouraging performance across different breast cancer types and breast densities.
If confirmed in larger clinical trials, the technology could eventually complement existing screening methods.
How Does the New Breast Cancer Blood Test Work?
The experimental test relies on a scientific field known as epigenetics.
Epigenetics examines chemical modifications that help determine how genes function without changing the underlying DNA sequence.
Every cell contains DNA, but not every gene is active at the same time.
Certain chemical markers help regulate which genes are switched on or off.
These markers are essential for normal cellular activity.
However, cancer can disrupt these regulatory processes.
As cancer develops, abnormal epigenetic patterns may appear in tumor cells.
When cells die, they release tiny fragments of genetic material and associated proteins into the bloodstream.
Some of this material comes from cancer cells.
The new test analyzes structures called nucleosomes, which consist of DNA wrapped around proteins known as histones.
Researchers use advanced microscopy and fluorescent markers to identify combinations of epigenetic changes associated with breast cancer.
Artificial intelligence then analyzes the complex molecular patterns to distinguish samples from patients with cancer and those without the disease.
Unlike tests that search primarily for cancer-related DNA mutations, this method examines the chemical markers associated with how genes are regulated.
This approach may provide additional information about tumor biology.
Researchers Reported 95% Accuracy in Detecting Early Breast Cancer
One of the most striking findings was the test’s ability to detect early-stage disease.
Researchers initially examined blood samples from 77 women with breast cancer who had been followed for at least five years at the Mayo Clinic in Florida.
Their samples were compared with those from 30 healthy women.
Using advanced computational analysis, the researchers developed models capable of recognizing molecular patterns associated with breast cancer.
The test achieved approximately 95% accuracy in distinguishing early-stage cancer samples from healthy controls.
The research team subsequently expanded its analysis with additional patient samples, including material obtained through collaborations with Sheba and Kaplan medical centers.
The investigators reported that the test maintained promising performance across different types of breast cancer.
Importantly, these findings come from selected research samples rather than a large population screening trial.
The reported accuracy does not mean the test will necessarily identify 95% of all breast cancers in routine medical practice.
Researchers still need to establish its sensitivity, specificity, false-positive rate, and real-world performance in larger and more diverse populations.
The Most Surprising Discovery: Hidden Aggressive Cancer Cells
While investigating the molecular characteristics of breast tumors, scientists discovered something unexpected.
Even tumors that appeared relatively nonaggressive could contain small populations of cells with highly aggressive characteristics.
These cells displayed distinctive epigenetic patterns.
Researchers believe such populations could help explain why some breast cancers return after apparently successful treatment.
A tumor is not necessarily composed of identical cancer cells.
Different cells within the same tumor may behave differently, respond differently to treatment, and possess varying abilities to invade surrounding tissues.
Some may be eliminated by treatment, while others may survive.
The researchers found that specific epigenetic signatures associated with aggressive cells could also be detected in blood samples.
This observation suggested that a blood test might reveal biological characteristics that are not fully captured by conventional tumor classification.
The discovery could help scientists better understand why some cancers recur despite initially favorable clinical findings.
Could the Test Predict Whether Breast Cancer Will Return?
Perhaps the most significant potential application of the technology is predicting breast cancer recurrence.
Cancer recurrence occurs when the disease returns after treatment and a period during which it was no longer detectable.
Even after successful surgery, radiation, chemotherapy, or other treatments, some patients remain at risk.
Doctors currently estimate this risk using several factors, including tumor size, lymph node involvement, cancer subtype, grade, and selected molecular tests.
However, these methods cannot predict every recurrence.
In the new research, scientists analyzed epigenetic patterns found in blood samples and compared them with long-term patient outcomes.
They discovered that certain molecular signatures were more common among women whose cancer later returned.
A predictive model based on these markers achieved an area under the receiver operating characteristic curve, or AUC, of 0.81 in one analysis.
An AUC measures how well a test distinguishes between groups. A value of 0.81 indicates promising discrimination, but it does not mean the test can predict an individual patient’s future with 81% certainty.
The researchers also reported stronger performance in a smaller analysis involving patients with available Oncotype DX results.
These findings suggest that blood-based epigenetic testing could eventually provide additional information about recurrence risk.
However, larger prospective studies are needed before such predictions can guide treatment decisions.
Why This Could Be Important for Women With Dense Breasts
Women with dense breast tissue face particular challenges during routine screening.
Dense tissue can make tumors more difficult to identify on mammograms because both dense tissue and many tumors appear white on the images.
This can reduce mammographic sensitivity.
Because the experimental blood test looks for molecular signals rather than imaging abnormalities, breast density may have less influence on its performance.
The researchers reported that their method performed well in samples from women with different breast densities.
This finding is especially interesting because women with dense breasts sometimes require additional imaging based on their individual risk factors.
A validated blood-based test could potentially provide another tool for evaluating cancer risk or investigating suspicious findings.
Nevertheless, the experimental test has not been shown to replace mammography, ultrasound, or breast MRI.
For now, established screening and diagnostic methods remain essential.
Could Blood Tests Eventually Replace Traditional Breast Biopsies?
The development also raises an important question: Could blood tests eventually eliminate the need for invasive breast biopsies?
Traditional biopsies involve removing a small tissue sample from a suspicious area so a pathologist can examine it under a microscope.
They are essential for confirming a breast cancer diagnosis and identifying characteristics that influence treatment.
Blood-based liquid biopsies offer a less invasive way to analyze certain molecular signals associated with cancer.
They may eventually help doctors monitor disease, assess treatment response, or estimate recurrence risk.
However, the new experimental test does not currently replace tissue biopsy.
A suspicious finding on mammography or another imaging examination still requires appropriate medical evaluation.
In many circumstances, tissue analysis remains necessary to confirm the diagnosis and determine the cancer’s biological characteristics.
The most realistic future application may involve using blood tests alongside established diagnostic techniques.
What Happens Next?
The next stage of research will determine whether the promising laboratory findings translate into better patient outcomes.
Scientists will need to examine the test in larger groups of women, including people without a previous breast cancer diagnosis.
Several important questions remain unanswered.
Can the test reliably identify cancer before it becomes visible on imaging?
How frequently might it produce false-positive results?
Could it identify aggressive tumors that would otherwise be missed?
Can its recurrence-risk predictions help doctors choose more effective treatments?
Most importantly, would using the test actually reduce advanced cancer diagnoses or improve survival?
These questions require carefully designed clinical trials and long-term follow-up.
A blood test that performs well in a research laboratory may not always achieve the same results in everyday clinical practice.
What Women Should Know About Breast Cancer Screening Today
While this new development is exciting, women should continue following established breast cancer screening recommendations.
The appropriate screening schedule depends on age, personal medical history, family history, genetic risk, and national medical guidelines.
Several changes deserve medical attention, including:
- A new lump or thickening in the breast or underarm.
- Unexplained changes in breast size or shape.
- Skin dimpling or unusual skin texture.
- Nipple inversion that develops unexpectedly.
- Bloody or unusual nipple discharge.
- Persistent, localized breast changes.
These symptoms do not automatically indicate cancer, and many have benign explanations.
However, persistent or unexplained changes should be evaluated by a healthcare professional.
Women with a strong family history of breast cancer or known inherited genetic mutations may require earlier or more intensive screening.
Early detection remains one of the most effective strategies for improving breast cancer outcomes.
A Potential New Era in Breast Cancer Detection
The latest research represents an exciting development in personalized cancer medicine.
By studying the molecular signatures circulating in blood, scientists may eventually detect breast cancer earlier and better understand which tumors are most likely to return after treatment.
The reported 95% accuracy in the initial early-stage detection analysis is particularly encouraging.
Equally important is the identification of aggressive cancer cell populations that might otherwise remain difficult to characterize.
Together, these findings suggest that future blood tests could provide information about both the presence of cancer and its underlying behavior.
However, the technology remains at an early research stage.
It is not yet a proven replacement for standard breast cancer screening, and its ability to improve long-term patient outcomes has not been established.
The real breakthrough may not simply be detecting cancer through a blood sample — but learning to recognize the molecular warning signs that reveal how a tumor behaves and whether it may return.
For millions of women affected by breast cancer, that possibility represents an important reason for cautious hope.
Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. The blood test described is experimental and is not a substitute for recommended breast cancer screening or diagnostic procedures.
